Akari Therapeutics PLC AKTX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:43 PM EDT
1.75quote price arrow up+0.05 (+2.79%)
Volume
1,176
Close
1.70quote price arrow down-0.07 (-3.95%)
Volume
259,612
52 week range
1.42 - 4.21

...

Loading . . .
  • Open1.76
  • Day High1.77
  • Day Low1.69
  • Prev Close1.77
  • 52 Week High4.21
  • 52 Week High Date02/22/21
  • 52 Week Low1.42
  • 52 Week Low Date11/10/20

Key Stats

  • Market Cap680,000.00
  • Shares Out400,000.00
  • 10 Day Average Volume0.39M
  • Dividend-
  • Dividend Yield-
  • Beta1.15
  • YTD % Change-8.11

KEY STATS

  • Open1.76
  • Day High1.77
  • Day Low1.69
  • Prev Close1.77
  • 52 Week High4.21
  • 52 Week High Date02/22/21
  • 52 Week Low1.42
  • 52 Week Low Date11/10/20
  • Market Cap680,000.00
  • Shares Out400,000.00
  • 10 Day Average Volume0.39M
  • Dividend-
  • Dividend Yield-
  • Beta1.15
  • YTD % Change-8.11

RATIOS/PROFITABILITY

  • EPS (TTM)-0.74
  • P/E (TTM)-2.29
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-17.972M
  • ROE (MRQ)-363.75%
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date08/31/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Akari Therapeutics PLC

There is no recent news for this security.

Latest From Our Partners

There is no recent news for this security.

Profile

MORE
Akari Therapeutics, Plc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. The Company’s lead product candidate, nomacopan inhibits both terminal complement activation and...
Ray Prudo M.D.
Chairman
David Solomon
Chief Executive Officer
Clive Richardson
Chief Operating Officer
Torsten Hombeck Ph.D.
Chief Financial Officer
Nigel Hernandez Ph.D.
Vice President
Address
24 W 40th St Fl 8
New York, NY
10018-1028
United States

Top Peers

SYMBOLLASTCHG%CHG
CRNX
Crinetics Pharmaceuticals Inc
20.37-0.78-3.69%
KDMN
Kadmon Holdings Inc
4.00+0.01+0.25%
MRNS
Marinus Pharmaceuticals Inc
18.88+0.38+2.05%
TCRR
TCR2 Therapeutics Inc
17.27+0.36+2.13%
GOSS
Gossamer Bio Inc
8.47-0.06-0.70%